Buprenorphine is used for opioid use disorder maintenance therapy. Its unique pharmacological profile that makes it safer than full agonists in overdose is:

• A Buprenorphine is a partial mu-opioid agonist with a ceiling effect on respiratory depression and very high receptor affinity ✓
• B Buprenorphine is a kappa agonist and does not cause respiratory depression
• C Buprenorphine undergoes rapid hepatic metabolism, preventing CNS accumulation
• D Buprenorphine acts only peripherally and does not enter the CNS

Explanation

Buprenorphine is a partial agonist at mu-opioid receptors with intrinsic efficacy lower than full agonists (morphine, fentanyl), resulting in a ceiling effect on respiratory depression at higher doses. Additionally, its extremely high receptor affinity (Kd in picomolar range) means it displaces full agonists from mu receptors and, conversely, naloxone requires higher doses and more frequent redosing to reverse buprenorphine overdose. This ceiling effect and high affinity combination makes it far safer in accidental overdose compared to full mu agonists.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.